Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Warby Parker Inc. (WRBY -2.39%)
Q4 2021 Earnings Call
Mar 17, 2022, 8:00 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Hello, everyone, and welcome to the Warby Parker fourth quarter and fiscal year financial results conference call. My name is Victoria, and I will be coordinating the call today. [Operator instructions] I'll now pass over to your host, Tina Romani, head of investor relations, to begin. Please go ahead.

Tina Romani -- Head of Investor Relations

Thank you, and good morning, everyone. Here with me today are Neil Blumenthal and Dave Gilboa, our co-founders and co-CEOs, alongside Steve Miller, senior vice president and chief financial officer. Before we begin, we have a couple of reminders. Our earnings release and slide presentation are available on our website at investors.warbyparker.com.

During this call and in our presentation, we will be making comments on a forward-looking nature. Actual results may differ materially from those expressed or implied as a result of various risks and uncertainties. For more information about some of these risks, please review the company's SEC filings, including the section titled Risk Factors in the company's latest 10-Q filings and the upcoming 10-K filing. These forward-looking statements are based on information as of March 17, 2022.

10 stocks we like better than Warby Parker Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

They just revealed what they believe are the ten best stocks for investors to buy right now... and Warby Parker Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 3, 2022

And we assume no obligation to publicly update or revise our forward-looking statements. Additionally, we will be discussing certain non-GAAP financial measures. These non-GAAP financial measures are in addition to and not a substitute for measures of financial performance prepared in accordance with GAAP. A reconciliation of these items to the nearest U.S.

GAAP measure can be found in this morning's press release and our slide deck available on our IR website. With that, it's my pleasure to turn the call over to Dave to kick things off.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

Thanks, Tina, and good morning, everyone. Thank you for joining us bright and early to discuss Warby Parker's fourth quarter and full year 2021 results as well as our outlook for 2022 and beyond. Before we dive in, we wanted to use this public forum to thank our Buy a Pair, Give a Pair partners, and congratulate our team on surpassing 10 million pairs of glasses distributed to people in need through our Buy a Pair, Give a Pair program. That means more than 10 million people now have the glasses they need to see, to learn, to work, and to provide for their families.

We're incredibly proud of the impact our team and partners are having. And we couldn't be more grateful to our customers and shareholders for making it possible. This impact is hugely motivating for our team and enables us to attract and retain the most passionate, curious-driven employees, who wake up every day obsessed with delighting customers and helping people see, and who in turn enable us to deliver strong financial results. And now turning to those results.

2021 was a record year for Warby Parker, and we're proud that our team delivered another year of sustainable growth. We grew revenue 37% to $541 million, while expanding adjusted EBITDA margin 270 basis points to 4.6%, up from 1.9% in 2020. This was achieved while delivering exceptional customer experiences, resulting in another year with a Net Promoter Score above 80%, while also making significant strides against our long-term strategic initiatives that will lead to sustainable growth for years and decades to come. We achieved these results in spite of many pandemic-related challenges, and in particular, in Q4, when we saw significant impairments during our peak selling season.

Team Warby, thank you for your continued perseverance and resilience. As we look back on 2021, it was incredibly exciting to celebrate so many milestones alongside team Warby. In addition to the 10 million pairs distributed, we became the first public benefit corporation to go public through a direct listing. We grew our active customer base by nearly 400,000 people, the most ever in a year to 2.2 million happy customers.

We opened 35 new stores, the most we've ever opened in a year, ending 2021 with 161 stores. And the performance of these 35 new stores are in line with the first year performance of stores we launched pre-COVID. As you may recall, in our S1, we discussed best-in-class unit economics targeting four-wall margins of 35% and paybacks in under 20 months. In 2021, we opened stores in nine new markets from Sarasota, Florida to Albuquerque, New Mexico and Richmond, Virginia.

And we continue to see a very consistent growth profile when entering new markets, with the entire market growing over 250% on average in the first year of opening a new store. We expanded our product assortment by launching 21 eyewear collections and introduced innovative first-to-market designs and constructions like our Tortoise Collage and Esme Edition, while also increasing our penetration of progressive lenses. And we made meaningful progress in our evolution from being primarily an eyewear company through a holistic vision care provider. We more than doubled the size of our contacts business and opened 36 new eye exam locations while hiring dozens of optometrists.

We opened our second optical lab, a 69,000 square foot facility in Las Vegas that further strengthens the vertically integrated supply chain we've built over the years and enables us to maintain the highest quality standards, exceed customer expectations, and lower costs. We also continue to focus on innovation in our category-leading e-commerce experience and digital tools. In 2021, we launched groundbreaking technologies like our Virtual Vision Test telehealth app, which allows eligible users to renew both glasses and contact lens prescriptions from anywhere at any time using just an iPhone in less than 10 minutes, and with continued adoption of our first of its kind, true to scale virtual trial. As I mentioned, we accomplished all these milestones while maintaining an industry-leading Net Promoter Score of more than 80.

Maintaining this metric is team Warby's North Star and has been since day one. It ensures we're continuing to deliver above and beyond products and experiences for our customers, which in turn, fuels our growth. And those happy customers are spending more with us than ever. Our average revenue per customer for the year was $246, up $28 or 13% versus 2020.

The largest increase we've ever seen in our 12 years since launch. That increase hasn't come from raising prices. It's come from two factors. First, more of our customers buying multiple categories of products from us.

For example, eye exams and contacts in addition to glasses. And second, an increase in the penetration of progressive lenses and higher price point frames. As a reminder, Progressives are our highest price point and highest margin product. And this remains an area where we are significantly underpenetrated relative to the rest of the market.

We want selling prescription classes for $95, and we have not changed this price point in the 12-plus years since launch. But over the years, we had introduced many other products at different price points that have led to increasing average order value and improving customer economics over time. And as we have introduced these new price points, we have not seen them impact demand. We know there's a lot of talk about inflation and we're seeing many companies increase prices, some because they're margins are getting squeezed and some opportunistically at the expense of their customers.

We started Warby Parker in large part because we were frustrated by the high price of glasses ourselves and wanted to create a much more customer-friendly alternative. As such, we will always focus on delivering great value and will leverage our structural advantage of controlling our supply chain, while eliminating wholesaler markets and license and fees to pass savings onto our customers. We were excited that we were able to maintain our high gross margins and continue to improve our customer economics without resorting to sweeping price increases. As others in our category continue to raise prices, our value proposition will become even stronger over time, which we expect will lead to even greater sustainable competitive advantage.

Of course, all of these positive results are due to the tireless efforts from our more than 3,000 team members who continue to be highly engaged. In a recent survey, 87% of employees said that they are proud to work for Warby Parker and 88% said they would recommend Warby Parker as a great place to work. And we couldn't be prouder of how our team has managed through the multiple waves of the pandemic, especially the most recent omicron outbreak. Omicron was particularly impactful given the unique seasonality in our business.

Because of FSA spending and digital insurance utilization at year end, we typically we see our highest sales days of the year between Christmas and New Year's. This year, omicron peaked during that same window in many of our biggest markets. As a result, we saw significantly lower retail foot traffic, staffing related store closures, and fewer eye exams. We also saw many other retailers in optical shops close several or all of their stores for days or weeks at a time.

This, in turn, led to fewer shoppers at neighboring stores and importantly, fewer people getting eye exams preventing them from shopping with us. We believe omicron resulted in nearly $5 million of lost sales in Q4 and over $15 million in Q1, stemming from fewer people shopping in our stores. What we've seen from prior COVID surges is that store traffic and productivity is not immediately bounced back and most customers don't immediately switch to shopping online. To do so, our customers need valve prescriptions and there's often a time lag for new exams to be scheduled.

When the delta variant emerged this summer, we saw significant declines to our productivity relative to the same period in 2019 followed by steady improvement for the following four months until omicron appeared. The subsequent omicron-related decline in retail productivity was nearly twice as severe as that from delta. As a result, we estimate that our Q4 revenue growth of 18% was negatively impacted by about four points, and our Q1 began with major headwinds. This is a temporary setback.

In the most recent weeks, we're experiencing a similar recovery curve to what we saw from other pandemic surges. And we remain as confident as ever in our long-term growth plans and the reacceleration of our growth in the coming months. While the pandemic has been disruptive to our business, it has been more disruptive to others in our category. This has enabled us to continue to grow our customer base and take the material market share over the last two years.

The U.S. eyewear market grew 5% from 2019 to 2021, while we grew 46%. In our differentiated omnichannel model, it's even more advantaged when consumers have easy access to eye doctors and prescriptions and feel fully comfortable shopping. As consumer behavior rebounds in our category, we believe we will benefit differentially as our 160-plus stores regain foot traffic and return to full productivity, while we continue to serve customers through our unique and industry-leading digital tools and e-commerce platform.

And with that, I'll pass it over to my co-CEO and co-founder, Neil, to talk through why we remain so excited for the rest of 2022 and beyond.

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Thanks, Dave, and good morning, everyone. We're as excited about our business and category as when we first started 12 years ago. As many of you know, our category is different from other consumer categories. Our core product, eyewear, is a combination of a health product and a fashion accessory.

We have a unique responsibility to provide vision while amplifying one's identity and style. We are fortunate to operate in a large and growing market, $160 billion globally and $44 billion in the U.S. alone. And one that provides essential products and services that are purchased in both strong and weak economic environment.

Several factors contribute to this growth and durability. First, most people need vision correction, with 76% of adults using some form of vision correction in 2021. Second, there is a natural replenishment cycle as prescriptions change or as people update their fashion preferences. Further, there are several macro factors contributing to rising vision correction needs and a steady influx of new customers who expect an exceptional Vision Care experience from an aging population and increased screen time usage to the acceleration of e-commerce penetration and increasing prominence of telehealth.

These trends support expectations that the industry will continue to grow and continue to become more favorable to our omnichannel approach. This is obviously exciting for us at Warby Parker. Despite being one of the only optical retailers to grow in 2020 and then accelerate that growth to 37% in 2021, reaching $541 million in revenue, we still just represent 1% of the U.S. market.

Another optical industry dynamic that makes it particularly appealing to our vertically integrated business model is that roughly 50% of the market is served by independent eye doctors and their optical shops that purchase frames and lenses wholesale and then resell them. The other half of the market is served by retail chains. And of that 50% of the market that are chain stores, roughly a third is owned by one company. Customers come to Warby Parker often after spending significantly more on their glasses because they either bought them from an overpriced optical chain or an independent optometry practice.

The other interesting dynamic of our industry is the prescription nature of the product. You need a valid prescription to buy glasses and contacts. Industrywide, approximately 70% of people buy glasses and contacts in the same location they have an eye exam. This benefits us as we open up more stores with exam suites and optometrists.

However, sales are negatively impacted when customers are not able to obtain prescriptions from us or their local optometrists due to omicron or other variants. While the prescription dynamic protect incumbents by providing barriers to entry in normal times, it leads to a slower ramp-up in other categories after a COVID surge. In spite of COVID, the eyewear market is poised to continue to grow faster than GDP, with an outlook of a 5.3% CAGR from 2022 to 2025. If there's one phrase that you hear repeated in the offices of Warby Parker, it's sustainable growth.

Our management philosophy is to drive predictable growth while expanding margins and delivering exceptional customer experiences to ensure future growth. Our long-term outlook remains the same. We plan to grow revenue consistently at 20% or more, maintain healthy gross margins of 58% to 60%, gain leverage, and expand adjusted EBITDA margins 100 to 200 basis points per year to achieve 20-plus-percent adjusted EBITDA margins. We also plan to continue to make appropriately sized investments in technology and in our team to ensure exceptional customer experiences that result in a Net Promoter Score greater than 80.

In 2022, we anticipate growth consistent with our philosophy of continued sustainable growth. We expect to grow top line 20% to 22% to $650 million to $660 million. Ahead of our direct listing in September before the onset of omicron, we provided a framework of 2022 net revenue growth of at least 25%. We arrived at our current range of 20% to 22% growth after taking into account the estimated $15 million impact from omicron in Q1 and assuming our stores reach 90% of pre-pandemic levels in Q2 and full productivity in Q4 based on the recovery curves we observed from the onset of COVID and from the emergence of delta.

We expect our gross margins to remain consistent at 58% to 60%. And we anticipate that we'll improve adjusted EBITDA 100 to 200 basis points. And of course, we expect to maintain a Net Promoter Score at or above 80. We see tremendous opportunity in front of us fueled by the natural tailwind we have as the business having launched purely online, selling just single vision prescriptions glasses.

We expect most of our 2022 growth to be driven by our retail channel as traffic and sales productivity rebound, particularly for our 63 urban locations whose productivity is currently 15 points lower than our suburban locations. We also plan to open 40 new stores in 2022 and end the year with 201 locations. Last year, we commissioned a third-party study that concluded our retail footprint has room to expand to over 900 retail locations in the U.S. while maintaining our best-in-class four-wall economics.

This is still a fraction of the 41,000 optical shops that exists today. As we continue to expand our product and service offering, we believe this will also expand our store footprint opportunity. And of course, we'll continue to serve customers via our leading e-commerce channel using unique tools like our Virtual Try-On to make the shopping experience convenient both online and offline. Having a flexible omnichannel model has enabled us to grow significantly faster than others in our category, and we'll continue to be a structural competitive advantage going forward.

On the product front, we expect our Progressives penetration will continue to increase, driving top line growth and gross margin expansion. Glasses with progressive lenses enable customers to see in the distance and up close. It's a product that is generally for customers 45 years and older. Our Progressive glasses start at $295 versus our single-vision product that starts at $95.

In addition to the significantly higher ASP, Progressives have a higher gross margin. We continue to be highly underpenetrated versus the industry with Progressives making up approximately 45% of all prescription glasses sold in the U.S. today. While it's just 20% of our prescription business, up from 16% in 2020.

We're particularly excited by the fact that today, Progressives purchases tend to skew more toward bricks and mortar given the complex nature of the prescription and the older customer demographic. So as we scale our retail footprint and our stores return to full productivity, we expect to see compounding growth of this product. We expect that our eyewear ASP and gross margin will continue to expand, thanks to our increased Progressives penetration given the $200 price differential between our single-vision glasses and our progressive glasses. We'll also continue to invest in our relatively new contact business, which doubled last year to 4% of our business and which we expect to grow at a similar pace in 2022.

The contacts market alone is over $5.5 billion, and contracts typically account for 15% to 20% of an optical retailer sales. So we believe we have many years of high growth ahead of us. We'll also continue to invest in our eye exam and vision testing business. Like contacts and Progressives, we are underpenetrated in the eye care given our e-commerce beginnings.

The eye care market is over $6.5 billion. And while exams typically account for 10% to 15% of an optical retailer sales, ours accounted for less than 2% of our sales in 2021. To drive growth, all 40 of our new in 2022 stores will offer eye exams. We anticipate ending the year providing eye exams in 154 stores, up from 107 in 2021.

We'll also transition 40 existing stores in states where we cannot directly employ optometrists to a PC model, which will give us greater control over the customer experience and enable us to recognize the exam revenue. Lastly, we'll continue to lead the way in telehealth and expand the capabilities and awareness of our Virtual Vision Test. Of course, we recognize businesses like ours are currently facing unique challenges, but we feel confident in our team's ability to navigate through them. Despite Apple's IDFA update and privacy changes, we've not experienced significantly higher customer acquisition costs.

Several years ago, we made the strategic decision to limit our dependency on paid social media platforms by reducing spend to less than 5% of our total media budget and instead leverage our highly flexible marketing model through a diverse mix of online and offline marketing channels. Given our customer base generally skews more affluent, we did not detect an increase in sales last year because of the federal stimulus in March and are therefore not lapping a onetime bump. Regarding shipping, the majority of our customer shipments are made through carriers where we have a negotiated fixed price multi-year agreement in place that do not include fuel surcharges. As Dave mentioned, we expanded our manufacturing footprint in the U.S.

by opening a second optical lab in Las Vegas last year. This enables us to make more glasses in-house, which leads to greater gross margins, higher quality and faster delivery times. We've been able to hire the talent required to scale operations faster than planned. In fact, we continue to attract and retain great talent across the organization from our manufacturing facilities to our stores, to our corporate offices.

This is thanks to our employer brand, which has only gotten stronger because of our actions during the pandemic to protect the health, safety and financial well-being of our employees as well as our due good efforts. Our team takes immense pride in our recent milestone of distributing 10 million pairs of glasses to people in need. While these are extraordinary times, team Warby is well prepared and fully energized to continue along the path of sustainable growth. With that, I'll turn it over to Steve to talk about our results and provide color on our 2022 financial outlook.

Steve Miller -- Senior Vice President and Chief Financial Officer

Thanks, Neil and Dave. Good morning, everyone. Jumping right in. Revenue for the full year 2021 came in at $540.8 million, up 37% versus 2020 and up 46% versus 2019.

We finished the year with 2.2 million active customers, an increase of 22% year over year. The power of our financial model stems from robust customer economics, which continued to strengthen. During the year, we grew average revenue per customer by 13% to $246. Additionally, our retention rates through 2021 continue to demonstrate the long-term relationship we're able to form with our customers, which we believe is unique in the optical industry.

Despite navigating through continued uncertainty for most of the year, these results demonstrate the strength of our brand and underscore the opportunity ahead as we execute against our growth strategies. For the fourth quarter, revenue came in at $132.9 million, up 18% year over year and up 42% compared to Q4 2019. The onset of omicron at the end of November has had a meaningful impact on our business given the unique seasonality aspects Dave talked through. Given the importance of Q1 within the optical industry and to our business, let me take a moment to walk you through the trends we have seen since the start of the year.

The disruption from omicron in January was twofold. First, the softer end to December resulted in a lower revenue deferral than we've historically seen in addition to the variant continuing to dampen traffic levels into January and February in our stores. We estimate the impact of omicron at $5 million in top line for Q4 2021 and $15 million in top line for Q1 2022, most of which we view as lost business and the lead up to the expiration of FSA dollars, with the impact split across Q4 and Q1 and largely in December and January. Given the unique seasonality of optical purchases and customer FSA usage behavior, we do not expect to recapture the majority of these lost sales and have reflected this impact in our first quarter and full year outlook.

With regards to e-commerce performance in the fourth quarter, while we saw an increase in e-commerce demand over the last 2 weeks of December, it did not offset the decline we experienced in retail traffic trends. For our business, the shift between retail and e-commerce may not be as natural or immediate as it is for other categories such as apparel, given the need for valid prescriptions and varying consumer comfort levels around purchasing eyewear online for the first time. For the fourth quarter, e-commerce represented 41% of our overall business versus 56% in 2020 and 34% in 2019. For the full year, e-commerce penetration was 46% versus 60% in 2020 and 35% in 2019.

E-commerce grew 96% during the fourth quarter of 2020. As such, Q4 2021 e-commerce is down 14% but up 69% versus 2019, representing a two-year CAGR of 30%. For the full year, e-commerce grew 5% on top of 83% growth last year, representing a two-year CAGR of 39%. Before shifting gears to gross margin and SG&A, I wanted to reiterate some of the fourth quarter seasonality dynamics that I spoke with you about last quarter.

Q4 is generally our lowest margin quarter given the revenue deferral and as we make several investments to support the important holiday selling season as well as the expiry of FSA benefits. These investments include: marketing to support and generate customer demand; investments in shipping as we expedite orders to meet holiday spending; increasing store staffing to accommodate higher traffic and extended store hours; and increasing our customer experience staffing to support higher demand; as well as elevated call volume related to flexible spending benefit questions. So while we believe our long-term outlook will show consistent high growth and steadily improving profitability on an annual basis as we saw in 2021 as the quarter-to-quarter picture may fluctuate. We've also added to our earnings slides a historical view of revenue by quarter going back to 2016.

As you can see, the revenue distribution is fairly equal across quarters in the same year with a significant step up in sequential growth from Q4 to Q1. We expect this cycle to continue post pandemic given the consistency we've seen in our business over many years prior. With that in mind, let's move on to gross margin. As a reminder, our gross margin unloaded and accounts for a range of costs, including frames, lenses, optical labs, customer shipping, eye doctors, store rents, and the depreciation of store build-outs.

Our gross margin also includes stock-based compensation expense for our optometrists and optical lab employees. For comparability, I will be speaking to gross margin, excluding stock-based compensation. Fourth quarter adjusted gross margin came in at 57.5% compared to 57.8% and 57% in 2020 and 2019, respectively. For the full year, adjusted gross margin came in at 59% compared to 58.9% in 2020 and 60.2% in 2019.

For the quarter, we have some unique costs and benefits impacting comparability as well as several operational puts and takes that I'll talk through. First, Q4 2020 benefited from a tariff rebate of approximately 70 basis points. Excluding this benefit, adjusted gross margin would have expanded. Next, the acceleration and penetration of our contacts business as a percentage of the total was the primary driver of slight moderation in fourth quarter gross margin.

As Neil mentioned, expanding our contact offering is a core part of scaling our holistic vision care offering and a key driver of increasing average revenue per customer. While contact lenses have a lower gross margin versus our other product offerings, they are accretive to gross margin dollars given the higher purchase frequency and subscription-like purchase cycle of this product. Additionally, we typically experience higher sales retention rates for customers that purchase contacts given the ability to meet all of their eye care needs within the Warby Parker ecosystem. As we talked with you about last quarter, there was a moderate drag on gross margin as our second optical lab in Las Vegas ramps to 100% operating capacity.

We expect the lab to reach scale in the back half of 2022, which will allow us to more efficiently serve our West Coast customers ultimately supporting leverage within gross margin. Lastly, we saw a benefit to gross margin from continued inventory and product strategy optimization as well as the expansion of our higher-margin Progressives business. For the full year, 2020 gross margin benefited from a tariff rebate of approximately 40 basis points. Excluding this benefit in 2020, adjusted gross margin expansion would have been greater in 2021, primarily driven by leverage on retail occupancy as we lap store closures last year and leverage as we continue to scale our higher-margin Progressives business, partially offset by the acceleration and penetration of our contacts business during the year.

Shifting gears to SG&A. SG&A for our business includes three main components: salary expense for our headquarters, customer experience and retail employees; marketing spend, including our Home Try-On program; and general corporate overhead expenses. Adjusted fourth quarter SG&A came in at $89.4 million or 67.3% as a percentage of net sales, in line with pre-pandemic spend levels as we make investments to support increased demand and deliver remarkable experience to our customers. The primary driver of the planned deleverage during the quarter was increased media investment.

As we spoke with you about in November, during the third quarter, we pulled back on marketing spend in response to the uncertainty presented by the delta variant with the intention to strategically redeploy those dollars in the fourth quarter. When the omicron variant emerged in late November, we made the strategic decision to continue to invest behind marketing, given the learnings we've gained after having navigated the first variant as well as the importance of the December selling season to our business. At less than 15% unaided brand awareness, each annual FSA expiry season is a prime opportunity to introduce new customers to the brand and reengage with existing customers. We want to be at the top of our customers' minds when purchase intent is potentially higher than in other seasons.

For the full year, on an adjusted basis, SG&A came in at $316 million or 58.4% as a percentage of net sales, an improvement of 3.2 points when compared to 2020 and about flat to 2019 as we realized leverage on both salaries and G&A, partially offset by investments in marketing. For the fourth quarter, adjusted EBITDA margin was negative 4.8%, in line with our guidance, driven by the investments I just spoke about versus 0.9% last year and negative 5.4% in 2019. Given the fixed nature of the Q4 investments already described, we believe we would have realized healthy flow-through on the $5 million of lost sales in the quarter and adjusted EBITDA would have been higher. For the full year, adjusted EBITDA margin was 4.6% versus 1.9% last year and 5.9% in 2019, reflecting continued cost discipline and realizing leverage across SG&A categories.

We finished the year with a strong balance sheet, reflecting $256 million in cash, which will continue to deploy deliberately to support our growth and operations. Looking ahead, while consumers will likely continue to be impacted by near-term macro headwinds and global uncertainty, the optical industry is healthy and growing, and we remain confident in the long-term sustainable growth algorithm we communicated at our investor day in September. As it relates to the full year 2022, we are guiding to revenue between $650 million and $660 million, which represents growth of approximately 20% to 22%. This outlook reflects the impact of an estimated $15 million of lost sales in the first quarter that I spoke about previously.

While we do not plan to guide on a quarterly basis, given the disruption of omicron to the start of the year and the corresponding impact to our full year 2022 guidance, we wanted to provide additional color. For Q1 2022, we're guiding to revenue between $153 million to $154.5 million, which represents growth of 10% to 11% year over year. This represents sequential top line growth of approximately 17% from Q4 2021 to Q1 2022. As you can see in our slides, pre-pandemic, we typically have seen sequential step-ups of 25% plus from Q4 to Q1 and would have expected a similar dynamic this year, if not for omicron.

Our full year guidance assumes continued retail recovery, reaching approximately 90% of pre-pandemic levels in Q2 and full productivity by year end. For contacts, in 2019, our stores opened for 12 months or more generated $2.6 million in revenue on average. While we remain optimistic we will ramp back to full productivity faster, we are maintaining a conservative stance as the timing and rate of recovery will continue to be impacted by changes in the COVID environment, alongside some of the broader macro headwinds facing the consumer and the economy, both known and unknown. Our outlook also reflects our expectations for earlier timing of new store openings.

Similar to 2021, we expect more than half of our openings to occur in the second and third quarters and underpins accelerated growth from Q2 forward. In line with the results delivered in 2021 and consistent with our long-term outlook for sustainable growth, we expect full year 2022 gross margin to be in the range of 58% to 60% and expect adjusted EBITDA margin improvement of one to two points, representing 5.6% to 6.6% adjusted EBITDA margin for full year 2022. We continue to expect sources of leverage to come from continued optimization of our retail and customer experience teams, a disciplined deployment of marketing spend and corporate overhead with revenue growth outpacing SG&A spend. In summary, we are very excited about the growth in the business, the continued recovery of our stores post-COVID and the opportunity in front of us.

To quickly recap some of the highlights we want you to take away from today's call. First, our business grew significantly, expanded profitability, and gained share despite being materially impacted by omicron, given its timing during FSA season as well as its disruption of customers' ability to obtain eye exams and new prescriptions. Second, our business is not significantly impacted by increased shipping costs, labor shortages, Apple's privacy updates, or lapping stimulus. Third, our business benefits from the reopening currently underway as our retail productivity and our channel mix normalize.

Fourth, our enthusiasm and energy for the success of our customers, our shareholders, our coworkers, and the communities we serve has never been higher. And we're excited for the year ahead. With that, Neil, Dave, and I are excited to take your questions. Operator, please open the line for Q&A.

Questions & Answers:


Operator

Thank you. [Operator instructions] And our first question comes from Mark Altschwager from Baird. Please go ahead. Your line is open. 

Mark Altschwager -- Robert W. Baird and Company -- Analyst

Great. Good morning. Thanks for taking my questions here. I guess to start off, I was hoping you could give us a bit of an update on how you're thinking about the competitive backdrop and maybe more specifically, competition at the lower end and some of the increasing inflationary pressures on the consumers.

And then related there, you talked a lot about the opportunities on the progressive front. Can you remind us how Warby's price point on Progressives compares to the competition? And how does your -- do you have that same pricing gap that you see with the single-vision glasses. Thank you. 

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

Thanks so much for your question. And first, as you mentioned, our Progressives glasses start at $295, which is a $200 step-up from our single-vision product at $95. When we price this product, the intent was to provide the same level of exceptional value. So we frequently see customers per spending $800 to $1,000 or more on a pair of Progressives and then they come and from us are able to get glasses still at a fraction of what they would typically cost.

Similarly, in the competitive dynamic, we still find that our customers tend to skew more affluent and are coming to us from high-end optical shops from optometric practices. We have not seen significant competitive pressure from the lower end of the market. We think in this inflationary environment, our pricing power just becomes more and more competitive and compelling to our customers.

Mark Altschwager -- Robert W. Baird and Company -- Analyst

That's great. A quick follow-up for Steve. If you could just give us a little bit more color on the bridge between the prior 25%-plus outlook and the current 20% to 23%. Even adjusting for the omicron disruption, the $15 million, the midpoint, maybe a couple of points below the prior outlook.

If you could give us a little bit more detail there, that would be great.

Steve Miller -- Senior Vice President and Chief Financial Officer

Sure. Thanks for the question, Mark. And just on the last part of your question on our progressive pricing versus the competition. So if our average price is $295, for a similarly quality progressive frame and lens, you're talking anywhere from $600 to $1,200, depending on the retailer.

So we believe that there still continues to be a tremendous pricing advantage that we offer based on the specific quality of our lens type and frame. In terms of the question regarding the full guide for 2022. So we attribute roughly $15 million of lost business in Q1 to omicron, which accounts for roughly three full points of growth, which gets you from our 25% guide down to 22%. We've also modeled in some conservative assumptions as it relates to recovery of our stores to 100% productivity.

And so that would account for the incremental two point of flexibility that we've built in our model. There's still a level of uncertainty in the environment. And although we're all optimistic that we're through the COVID era. It is not officially done yet.

And while our stores are on their path to recovery and we're optimistic they will get back to 100% before year-end and 90% in Q2, we wanted to build in a level of conservatism just that we think is prudent.

Mark Altschwager -- Robert W. Baird and Company -- Analyst

Great. Best of luck. Thank you. 

Operator

Our next question comes from Kimberly Greenberger from Morgan Stanley. Please go ahead.

Kimberly Greenberger -- Morgan Stanley -- Analyst

Oh, thank you so much. Good morning, Steve. I just wanted to follow up on your answer to Mark's question there, if we could just start there. On the recovery in your urban store productivity, I'm wondering if you can help us understand if, first of all, the suburban stores have improved their productivity back to 2019 levels? In other words, have you seen post the original onset of COVID in the spring of 2020, have you seen your suburban stores retrace back and recover to full productivity? And then on the urban store recovery embedded in your revenue guidance for 2022, are you assuming that office workers go back to their in-office habits of 2019 in order to get you back to that pre-pandemic level of productivity in your urban stores?

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Thanks, Kimberly. This Is Neil. So our suburban stores have not yet reached full productivity. And again, our urban stores are more than 15 points below that.

We are assuming sort of what we're seeing in our own business, which is we're calling back our New York headquarters starting April 5. And we are also returning to the office mandatory three out of five days a week. So we are assuming a ramp to full productivity, but not necessarily full traffic to pre-pandemic levels. And part of our increases in productivity continued to be driven by increased progressive penetration, eye exams, contact sales, our urban stores have been impaired, not just because of reduced office worker traffic but in many neighborhoods reduce tourism as well that we anticipate will rebound.

So we do anticipate that the urban stores will return to full productivity at a slightly slower pace than our suburban locations.

Kimberly Greenberger -- Morgan Stanley -- Analyst

OK. Great, Neil. That's great color. And I just wanted to step back for a second and talk about the strategies that you might have in place either in 2022 or 2023 to enhance the Warby Parker proposition to consumers who have vision insurance.

Any sort of incremental strategies or new ways of really tackling that insured market?

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Sure. Thanks for the question, Kimberly. We believe insurance remains a massive opportunity for us. And within that, really think of it as three distinct opportunities.

So the first is expanding our in-network relationships. We're currently in network with UnitedHealthcare, which covers roughly 20 million lives as well as being offering in-network benefits to large employers like GE and Boeing, and you'll see us continue to deepen relationships like this, and we'll have more news to share on that front later this year. The second category within the world of insurance is building awareness about out-of-network benefits. And we did a recent survey of a couple of thousand consumers and found that industrywide, most consumers are spending $130 out of pocket when they use their in-network benefits.

But if those same consumers came to Warby Parker, they would spend $0 out of pocket to purchase single-vision glasses. And we believe that there is a massive opportunity here to create education, both online and in our stores around how consumers can use those out-of-network benefits to pay even less at Warby Parker. And then the third is really rethinking vision insurance and continuing to innovate as we have in other parts of the industry. And all the aspects of our expansion into a holistic vision care provider continuing to open exam rooms throughout the country, continuing to hire optometrists, investing in telehealth, expanding our contacts business, all create the foundation that we believe will enable us to create more innovation in the category over a longer time period.

Kimberly Greenberger -- Morgan Stanley -- Analyst

OK. Great, Neil. That's great color. Thank you so much.

And I just  tackling that insured market. Thank you. 

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Thanks for the question, Kimberly. 

Operator

Our next question comes from Paul Lejuez from Citigroup. Please go ahead. Your line is open. 

Paul Lejuez -- Citi -- Analyst

Hey. Thanks, guys. Thanks, guys. I'm curious if you could talk about the drivers of your sales assumption for F '22, just in terms of active customer growth versus spend per average customer? And then also curious about any bottlenecks that you're running into getting stores open on the construction front or staffing front? And then last, just the number of stores that you're growing in new markets versus existing markets in '22.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

Cool. Thanks for the question, Paul. I'll answer the first part of the question and then turn it over to Neil. In terms of sales drivers and assumptions around active customer growth, one of the nice consistent aspects of our financial model really has been the consistency around which we've grown active customers really in the 22% zone, so call it the low 20s.

And coupled with that, we've seen our ability to increase average revenue per customer on a consistent basis. We've talked about how that's up 13% year over year to $246. And so we believe that we will continue to be able to deliver active customer growth in a very consistent way in line with how we have done that. And we also believe that we'll continue to drive increases in average revenue per customer, maybe not as high as 13%, but certainly consistent with how we've done so in the past.

From a demand generation perspective, there are a few factors to keep in mind that really underpin our ability to acquire customers. So one is opening up new stores. We plan to open up 40 new stores this year. 25 of them are in Q2 and Q3, which really underpin our accelerating growth targets over the course of the year.

And we plan to continue to deploy a very disciplined marketing spend. We're very conscious of the equation between revenue growth and CAC and similar to this year and previous years, we want to make sure that our revenue growth is growing appreciably faster than CAC. And so ultimately, we're increasing contribution profit and contribution margin on a per customer basis. So those are some of the factors and drivers that go into our customer acquisition model.

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

And Paul, this is Neil. We are not seeing bottlenecks or inability for us to complete construction and maintain sort of our store opening timelines. And these new stores are performing in line with expectations and in line with per share performance of the stores that we launched pre-COVID. So trending toward our targeted 20-month paybacks and on 35% four-wall EBITDA.

The other thing is in 2021, we opened nine stores in new markets out of 35 stores that we open, and we plan to sort of continue to open up in new markets in sort of a similar proportion.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

The rough split this year, Paul, is of the 30 markets we're opening, 25 will be existing markets and five will be new markets. So as Neil indicated, very similar to the split as to last year, but with this year, indexing a little bit more toward existing.

Paul Lejuez -- Citi -- Analyst

Got it. Thank you, guys. Good luck. Thank you. 

Operator

Our next question comes from Brooke Roach from Goldman Sachs. Please go ahead.

Brooke Roach -- Goldman Sachs -- Analyst

Good morning, and thank you so much for taking our question. Neil, Dave, I'd love to hear a little bit more about your plans for Warby's brand awareness campaigns and marketing strategy to drive that new customer growth into 2022 and beyond. Are there any insights that you can share on the marketing efficiency that you're seeing? And any noticeable differences between existing markets or new markets for the brand?

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Sure. This is Neil. I'll start. I think first, we should probably just talk a little bit about our marketing efficiency.

And we know that a lot of companies are seeing challenges because of the IDFA changes. We have not and that's because we made a very deliberate decision several years ago to reduce our dependency on social media platforms, and it now represents less than 5% of our media spend.¡We did see CAC in Q4 was elevated due to increased spend really in anticipation of our peak sales season, and we believe that CAC was indeed impacted by the decrease in sales due to omicron. That being said, if we believe the fundamentals related to our customer acquisition model remains strong. Having average revenue, it's growing faster than CAC.

Also increased retail productivity tends to benefit our CAC as stores are marketing vehicles, and we tend to see a higher percentage of new customers in our stores vis-a-vis our e-commerce channel. And one of the ways that we raise awareness is by opening these stores and making them super beautiful. And this week, we're opening up a store in High Park Village in Tampa. It's our second location in Tampa -- I'm sorry, our third location in Tampa, and it's just starting the exterior.

It is already sort of generating, I think, a lot of attention in that community. So you'll continue to see a good mix of performance and brand marketing that enables our customers to fall in love with us. And of course, just know that we exist.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

And I would just add that from a marketing standpoint, we've never been overly dependent on paid marketing. Our customers have been and remain our best marketing channel and we're excited to maintain our industry-leading Net Promoter Score. And into this day, the majority of our customers continue to learn about us through word of mouth, and we expect that to continue to be the case.

Brooke Roach -- Goldman Sachs -- Analyst

Thank you. And if I could just ask one quick follow-up to some of the prior questions regarding the omicron impact. Thanks for all of the color that you've provided so far. But I'd love to hear a little bit more about the signals that you're seeing in the business.

Maybe the suburban stores versus the urban stores that give you confidence that the lower store productivity that you're seeing through the end of February is truly a function of just omicron relative to maybe a more challenging consumer backdrop given the inflationary pressures on the consumer's wallet. Thank you. 

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

One thing to add, we continue to see is increased sort of conversion in our stores and again, increase or sort of stable Net Promoter Score. And we're not seeing sort of any concern or hearing from our customers necessarily about pricing. If anything, we're hearing sort of reinforcement around sort of the value that we continue to provide. This is also -- we've now lived through multiple ways of the pandemic, and we've seen similar patterns where when there are COVID outbreaks in a certain geography, there's an immediate drop in retail traffic.

And then because of the prescription and nature of our product, there's not an immediate bounce back like you might see in some other consumer categories. And so we have seen multi-month recovery curves, and we're seeing consistent patterns coming out of omicron that give us confidence that store productivity will continue to increase.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

And just adding to that with some of the numbers that we shared in our investor slides, where we trying a spotlight on the recovery curve at the onset of omicron. I think one of the interesting things we've all seen from omicron is how quickly the impact occurred. And you can see that our stores at the beginning of December, we're at 90% of productivity and pretty quickly dropped to 75% by year end. And they've rebounded now rather rapidly to the mid-80s.

And as we project our recovery curve over the course of the year. And as a reminder, we believe that our stores will be at 90% by Q2, 100% by the full year. That is informed by how our stores have rebounded and recovered through the various time frames of the pandemic, the original onset of COVID, the onset of delta and now the onset of omicron and the recovery through it.

Brooke Roach -- Goldman Sachs -- Analyst

Thanks so much. I'll pass it on. 

Operator

Our next question comes from Oliver Chen from Cowen. Please go ahead. 

Oliver Chen -- Cowen and Company -- Analyst

Regarding Holistic Vision Care, would love your thoughts on the Virtual Vision testing telehealth app ahead and key catalysts there. And how the customer profile looks as well as the technology road map. And then as we think more near-term, with FSA and some changes in FSA in terms of the legislation, what should we be to monitoring and how that may impact your business and what's embedded in guidance? And you also mentioned macro factors, which are -- many of them are out of your control. But I was curious about which ones are most sensitive to store traffic and other factors.

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Thanks, Oliver, for the questions. I'll start with the telehealth one. So we remain incredibly excited about the prospect of telehealth making it easier, faster, cheaper for our customers and patients to renew prescriptions and get new prescriptions. And we believe that we're uniquely positioned to bring some of this technology to market.

And we're seeing very positive results from our Virtual Vision Test. It's still a new product. We introduced it a few months ago, but are getting incredible feedback from customers who use it to renew their prescriptions in just a few minutes for glasses and contacts from home. And you'll see us this year introduce new capabilities and new features that will make it even easier for us to prescribe additional products and extend the reach of our doctors.

We also are excited about the potential of using other forms of telehealth, including in our stores. And continuing to invest in technology that make it easier for our eye doctors to serve more patients and drive efficiency in that part of our business.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

I think from an FSA perspective, sort of we welcome legislation that makes the use of those funds more flexible. That being said, we found that customers tend to be pretty uninformed on changing legislation or even if their expiration date is not December 31st, there's just a perception of that. So while these changes may immediately take effect, we think that it will take several years for it to significantly influence customer behavior is almost a similar dynamic, but even vision insurance, where many customers don't fully understand how their vision insurance works and the fact that it doesn't protect against catastrophic risk. And that's effectively a prepayment plan often with a high deductible.

So the FSA changes may impact some seasonality in years ahead, but we don't expect it to significantly impact sort of our plans this year.

Oliver Chen -- Cowen and Company -- Analyst

OK. And on the macro side, just would love your take. And lastly, hopefully, there are no really scale new variants, but there's always news about things happening. As you think longer term, are there ways to the future proof of your business with respect to this dynamic? Would love your thoughts as you evaluate long-term strategy.

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

One of the things that we did see in our business as traffic declined in our stores, conversion increased significantly. So as we think about retail productivity and our plans in '22, in particular, we feel like we don't need to model to get back to 100% or even higher traffic in order to reach full productivity and achieve our plans. We think the macro environment tends to impact other categories more than the optical industry. Historically, the optical industry grows at a rate higher than GDP.

On the same token, decreased traffic to neighboring stores, right, increases traffic into our stores. So that's something that we'll continue to monitor. I think that we -- when it comes to the variant and managing through the pandemic, we were an early mover and implemented health and safety protocols quickly. That earned us goodwill with our customers and our employees, and we continue to benefit from that today in our ability to recruit and retain top talent.

And that's seen in our employee engagement scores. That's seen in our turnover rates. I think all businesses saw lower than usual churn, employee turnover in 2020 and then elevated in 2021. Ours was relatively stable.

So we feel really great about that. And we continue to be just a preferred employer because of our culture, because of our social innovation.

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

And also just the digital capabilities that we have that are unique to our business in our category, will continue to ensure that we have flexibility to serve customers regardless of kind of what happens in terms of future variants or other surprises and has enabled us to continue to take meaningful market share throughout the pandemic, it enabled us to serve customers when we had to close all of our stores. And so kind of the omnichannel model that we have in those investments will continue to ensure that we are better positioned to serve customers regardless of kind of unexpected events that they pop up.

Oliver Chen -- Cowen and Company -- Analyst

Very helpful. Thank you. Best regards. 

Operator

And our final question for today comes from Mark Mahaney from Evercore. Please go ahead. 

Mark Mahaney -- Evercore ISI -- Analyst

Thank you. You mentioned the 40 new stores you're rolling out this year are all going to have eye exam capability. Can you just remind us how many of your existing stores have that? And what the difference is and the productivity of the stores that have eye exam capability versus those that don't? And if it's a large gap, the possibility or the appealing feasible idea of retrofitting all stores to have that is? Thank you. 

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

Sure. Hi, Mark. Thanks for the question. Approximately 107 of our stores today have eye exam capabilities.

Roughly 40 of those we refer to as employed ODs, where we employ the doctor and recognize the revenue from the doctor. We've got another 60 or so independent ODs where we lease the doctor a small amount of space, typically adjacent to our store. We do not recognize the revenue from those eye exams, but we're optimistic, although we can't track it that the customer gets an examine then places an order in our store. As a reminder, roughly 70% of all prescription eyewear is purchased at the same place where an individual gets an eye exam.

That number is higher for our stores. So we're optimistic as we continue to roll out eye exam capabilities everywhere. There'll be an elevated conversion rate where we're benefiting not just from the eye exam revenue, but from a conversion of that exam into a sale. And roughly just 2% of our business today, as a reminder, comes from the sale of eye exams.

The PC model that Neil talked about in his prepared remarks, we're planning to roll out roughly another 30 to 40 PC model stores this year, and that will enable us in a market where we needed to partner with an independent OD will be able to, for all intents and purposes, have an employer like relationship with that OD and recognize the revenue from those eye exams and have a bit more control over the customer experience. In terms of the incremental costs to add an eye doctor, the eye doctor, him or herself, more than pays for him or herself by virtue of the fact that we sell eye exams and our eye point and slots are generally booked. We tend to book in 20-minute increments versus 10-minute increments. So we do believe that, that in and of itself is a factor that makes our work environment a bit more pleasant and manageable for an eye doctor at a Warby store versus at a competitor store.

The cost to build out the space is negligible. It's well south of $100,000 and accounts for approximately 200 to 250 square feet. Stores with eye doctors generate moderately more revenue than stores without for the understandable reason. In terms of payback, we've seen very consistent paybacks for our stores at 20 months or below, and that also applies to stores where we add this eye doctor capability.

Mark Mahaney -- Evercore ISI -- Analyst

Thank you, Steve.

Operator

Thank you so much. And this brings us to the end of our Q&A session today. I would now like to pass the call back over to Neil for any final remarks.

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Great. Thank you all for your great questions today. Dave, Steve, and I are so proud of what we and the team have accomplished in 2021. And we're incredibly excited for the months and years ahead.

If you have any additional questions or follow-ups, please feel free to reach out to Tina or our investor relations inbox at [email protected]. And we look forward to chatting with you all again in May. Thank you.

Operator

[Operator signoff]

Duration: 69 minutes

Call participants:

Tina Romani -- Head of Investor Relations

Dave Gilboa -- Co-Founder and Co-Chief Executive Officer

Neil Blumenthal -- Co-Founder and Co-Chief Executive Officer

Steve Miller -- Senior Vice President and Chief Financial Officer

Mark Altschwager -- Robert W. Baird and Company -- Analyst

Kimberly Greenberger -- Morgan Stanley -- Analyst

Paul Lejuez -- Citi -- Analyst

Brooke Roach -- Goldman Sachs -- Analyst

Oliver Chen -- Cowen and Company -- Analyst

Mark Mahaney -- Evercore ISI -- Analyst

More WRBY analysis

All earnings call transcripts